(Q37126658)

18 August 2017

1 reference

title

An update on methotrexate pharmacogenetics in rheumatoid arthritis (English)

1 reference

18 August 2017

1 reference

1 reference

Prabha Ranganathan

1

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

4

1 reference

18 August 2017

439-451

1 reference

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

18 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Methotrexate hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Mammalian ABC transporters in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

MRP3, an organic anion transporter able to transport anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Molecular action of methotrexate in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Relation between crossbridge structure and actomyosin ATPase activity in rat heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A Polymorphism, R653Q, in the Trifunctional Enzyme Methylenetetrahydrofolate Dehydrogenase/Methenyltetrahydrofolate Cyclohydrolase/Formyltetrahydrofolate Synthetase Is a Maternal Genetic Risk Factor for Neural Tube Defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Haplotype variation and linkage disequilibrium in 313 human genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Assessing the cost-effectiveness of pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

Overview of the pharmacoeconomics of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.4.439

21 January 2018

Identifiers

DOI

10.2217/14622416.9.4.439

1 reference

18 August 2017

1 reference

PubMed ID

18384257